TigerOak Management L.L.C. Invests $86,000 in Novavax, Inc. (NASDAQ:NVAX)

TigerOak Management L.L.C. purchased a new stake in Novavax, Inc. (NASDAQ:NVAX) in the 4th quarter, HoldingsChannel reports. The firm purchased 10,640 shares of the biopharmaceutical company’s stock, valued at approximately $86,000.

A number of other large investors also recently bought and sold shares of the business. Spire Wealth Management purchased a new stake in shares of Novavax in the fourth quarter valued at approximately $29,000. KBC Group NV boosted its holdings in Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 3,917 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 1,598 shares during the last quarter. US Bancorp DE increased its position in shares of Novavax by 3,538.8% during the third quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 11,961 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in Novavax in the 3rd quarter valued at $158,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Insider Transactions at Novavax

In other news, Director James F. Young sold 5,400 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the sale, the director now directly owns 51,760 shares of the company’s stock, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 in the last quarter. Company insiders own 1.00% of the company’s stock.

Novavax Stock Performance

Shares of Novavax stock opened at $8.19 on Friday. The business’s 50 day moving average price is $8.74 and its 200 day moving average price is $10.25. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -3.62, a PEG ratio of 63.06 and a beta of 2.14. Novavax, Inc. has a one year low of $3.81 and a one year high of $23.86.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.